RepliCel pursuing non-diluting grant funding

RepliCel Life Sciences

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has retained The FreeMind Group, an international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private foundations.

“We have a number of strategic clinical and non-clinical projects which are ideally positioned for external collaborations and non-dilutive funding,” president and CEO, Lee Buckler, said in a statement.

These include basic research, manufacturing optimization, product development, and clinical objectives, which have the potential to create significant intellectual property and shareholder value.

“FreeMind has a proven track record and commitment to success-based remuneration that convinces us they will bring significant value to our programs,” he added.